

REMARKS

Claims 46-58 were pending. Applicants have hereinabove cancelled without prejudice claims 48-58 and have submitted new claims 59-70. No new matter has been added by this Amendment. Accordingly, applicants respectfully request that the Examiner enter this Amendment. Upon entry of this Amendment, new claims 59-70 will be pending.

Rejection Under 35 U.S.C. § 103(a)

In the April 20, 2007 Office Action, the Examiner rejected the previously pending claims under 35 U.S.C. § 103(a) as being unpatentable over U.S. Patent No. 6,517,863 ("LaTorre") in view of WO 00/76486 ("Ballantone").

In response, applicants respectfully traverse the Examiner's rejection under 35 U.S.C. § 103(a). Without conceding the correctness of the Examiner's bases for rejecting the previously pending claims and to expedite prosecution of the instant application, applicants have hereinabove cancelled without prejudice claims 46-58 and have submitted new claims 59-70, which applicants maintain are not obvious over the cited references.

Applicants note that new claim 59 is the only presently pending independent claim. New claim 59 recites:

A method for abrading human or animal tissue comprising abrading the tissue with a bioactive material which comprises between about 30% and about 96% by weight of silicon dioxide oxide (SiO₂), between about 0% and about 35% by weight of sodium oxide (Na₂O), between about 4% and about 46% by weight calcium oxide (CaO), and between about 1% and about 15% by weight phosphorus oxide (P₂O₅), with the proviso that the tissue is not nail tissue.

(Emphasis supplied)

Applicants have, *inter alia*, analyzed the scope and content of the cited references and have ascertained the differences between the cited references and the pending independent claim in order to evaluate properly the Examiner's obviousness rejection. Having done so, applicants maintain that in sharp contrast to the pending independent claim, the cited references taken together or alone do not suggest applicants claimed methods for abrading human or animal tissue with bioactive materials wherein the tissue is not nail tissue such as fingernails or toenails. The cited references will be addressed in more detail below.

Reviewing the scope and content of LaTorre, it is clear that the reference merely describes compositions and methods for treating nails (i.e., fingernails and toenails) and adjacent tissues with interlinked particles of bioactive glass to form layers of hydroxyapatite. For example, methods described by LaTorre relate to applying effective nail-enhancing amounts of bioactive glass compositions to nails and adjacent tissues for a sufficient time to cause formation of hydroxyapatite or other calcium phosphate mineral layer on the nail surface. (See Abstract) LaTorre also describes soaking nails in aqueous solutions to allow hydroxyapatite formation. (See, Col. 2, lines 48-50) LaTorre refers to the use of such compositions to form a protective layer on the nail body to harden and increase the durability of the nail. (See, Col. 3, lines 1-6) LaTorre further describes the benefits of keeping the compositions in contact with the nail for an extended period of time. (See, Col. 6, lines 2-3). Likewise, both of LaTorre's Examples are directed to treating fingernails with either a paste (Example 1) or solution (Example 2) to harden and strengthen nails. In sharp contrast to the pending independent claim it is quite clear that LaTorre is completely silent with respect to using bioactive materials on any non-nail tissue, such as fingernails or toenails, much less using bioactive material to abrade such non-nail tissue.

Applicants maintain that the secondary reference Ballantone does not cure the

deficiencies of LaTorre recited above. Indeed, the Examiner simply relied to Ballantone for its description of particular metal ions. Ballantone like LaTorre is completely silent with respect to using bioactive materials on non-nail tissue.

Accordingly, applicants respectfully submit that new independent claim 59 is not rendered obvious by LaTorre in view of Ballantone.

Dependent Claims

For the reasons stated above with respect to new independent claim 59, applicants maintain that new dependent claims 60-70 are not rendered obvious by the cited references alone or in any combination.

Obviousness-Type Double Patenting Rejections

In the October 22, 2007 Final Office Action the Examiner rejected the pending claims on the ground of non-statutory obviousness-type double patenting based on U.S. Patent No. 7,141,520 (“the ‘520 Patent”) and U.S. Patent No. 7,192,602 (“the ‘602 Patent”). The Examiner also provisionally rejected the claims for non-statutory obviousness-type double patenting based on U.S. Application Serial No. 10/673,596 (“the ‘596 Application”).

Applicants respectfully traverse the Examiner’s obviousness-type double patenting rejections based on the ‘520 and ‘602 Patents. Neither of these patents suggest methods for abrading human or animal tissue, much less where human or animal tissue is specifically not nail tissue. Accordingly, applicants respectfully request that the Examiner reconsider and withdraw this basis for rejection.

With respect to the ‘596 Application, applicants respectfully request that the Examiner hold in abeyance the provisional non-statutory obviousness-type double patenting rejection of the claims base on the ‘596 Application until claims in at least one of the ‘596

Application and the instant application have been allowed. Applicants can then determine whether a terminal disclaimer should be submitted in the instant application or in the '596 Application.

Conclusion

In view of the foregoing, applicants respectfully request that the Examiner reconsider and withdraw the rejections set forth in the October 22, 2007 Final Office Action and allow the presently pending claims, namely claims 59-70.

No fee is believed to be necessary in connection with the filing of this Amendment. If any additional fee is deemed to be necessary, applicants hereby authorize such fee to be charged to Deposit Account No. 50-0540.

If a telephone interview would be of assistance in advancing prosecution of this application, applicants' undersigned attorney encourages the Examiner to telephone him at the number provided below.

Respectfully submitted,

Dated: October 30, 2007

/Robert E. Alderson/
Robert E. Alderson, Reg. No. 44,500
KRAMER LEVIN NAFTALIS & FRANKEL LLP
1177 Avenue of the Americas
New York, New York 10036
(212) 715-9100 (telephone)
(212) 715-8000 (facsimile)